|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 950 F Street, NW |
Address2 | Suite 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31350-12
|
||||||||
|
6. House ID# 306540000
|
TYPE OF REPORT | 8. Year | 2013 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Paul J. Larsen, Deputy Compliance Officer & Assistant General Counsel |
Date | 01/21/2014 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 2216, Military Construction and Veterans Affairs, and Related Agencies Appropriations Act, 2014: Provisions related to Veterans Affairs Administration regulation and funding, VA health benefits
H.R. 2217, Department of Homeland Security Appropriations Act, 2014: Provisions related to Customs and Border Control Agency funding, drug imports
H.R. 2397, Department of Defense Appropriations Act, 2014: Provisions related to bio-defense
H.R. 2410, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2014: Provisions related to FDA regulation and funding, sequestration, drug importation
H.R. 2725, Food and Drug Administration Safety Over Sequestration Act of 2013: Provisions related to FDA user fees
H.R. 3547, Consolidated Appropriations Act: Provisions in the appropriations bills identified above
H.J. Res. 59, FY14 Continuing Resolution
Issues related to implementation of The Budget Control Act of 2011: Public Law No. 112-25: Provisions related to sequestration
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
Jennifer |
Bryant |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Lea |
Fisher |
|
|
|
Peter |
Fotos |
|
|
|
Sascha |
Haverfield-Gross |
|
|
|
Valerie |
Jewett |
|
|
|
David |
Korn |
|
|
|
Colleen |
Maloney |
|
|
|
Cara |
Moon |
|
|
|
Anne |
Pritchett |
|
|
|
Lori |
Reilly |
|
|
|
Jennifer |
Romans |
|
|
|
Nick |
Shipley |
|
|
|
James M. (Mit) |
Spears |
|
|
|
Matt |
Sulkala |
|
|
|
Jeffrey |
Francer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 22, Foreign Counterfeit Merchandise Prevention Act: Provisions related to counterfeiting
H.R. 845, Saving High-Tech Innovators from Egregious Legal Disputes Act of 2013 (the SHIELD Act): Provisions related to patent litigation
H.R. 2024, End Anonymous Patents Act: Patent owner information provisions
H.R. 2582, PATENT Jobs Act: Provisions related to patent user fees
H.R. 2605, Manufacturing Innovation in America Act of 2013: Provisions related to patent tax boxes
H.R. 2639, Patent Litigation and Innovation Act: Patent litigation proposals
H.R. 2766, STOP Act: Provisions related to business method patents
H.R. 2985, Combination Drug Development Incentive Act of 2013: Provisions related to exclusivity for combination drugs
H.R. 3116, MODDERN Cures Act of 2013: Provisions related to diagnostics and exclusivity
H.R. 3309, Innovation Act: Provisions related to patent litigation reform
H.R. 3349, Innovation Protection Act: PTO Fee Diversion
H.R. 3540, Demand Letter Transparency Act: Provisions related to patent demand letters
H.R. 3709, Protecting Consumer Access to Generic Drugs: Provisions related to patent settlements
S. 214, Preserve Access to Affordable Generics Act: Provisions related to patent settlements
S. 504, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements
S. 626, Prize Fund for HIV/AIDS Act: Medical prize provisions
S. 627, Medical Innovation Prize Fund Act: Medical prize provisions
S. 712, Patents for Humanity Program Improvement Act of 2013: Transferability of PTO vouchers provisions
S. 866, Patent Quality Improvement Act of 2013: Business methods patents provisions
S. 1013, Patent Abuse Reduction Act of 2013: Patent litigation provisions
S. 1612, Patent Litigation Integrity Act: Patent litigation provisions including bonding
S. 1720, Patent Transparency and Improvements Act of 2013: Provisions related to patent litigation and other reforms
Biopharmaceutical innovation policy issues
Biologics data protection issues
Draft legislation on trade secret issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), Patent & Trademark Office (PTO), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Leo |
Farber |
|
|
|
Lea |
Fisher |
|
|
|
Peter |
Fotos |
|
|
|
Valerie |
Jewett |
|
|
|
David |
Korn |
|
|
|
Colleen |
Maloney |
|
|
|
Cara |
Moon |
|
|
|
Jennifer |
Romans |
|
|
|
James M. (Mit) |
Spears |
|
|
|
Matt |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 2674, 340B Program Improvement Act: Provisions related to 340B Drug Pricing Program (112th Congress)
H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013: Provisions related to supply chain security
H.R. 2090, Patient Choice Act of 2013: To permit provisional approval of fast track products
H.R. 3204, Drug Quality and Security Act: Provisions related to pharmacy compounding and supply chain
H.R. 6584, Verifying Authority and Legality In Drug Compounding Act: Provisions related to drug compounding (112th Congress)
H.R. 3742, Antibiotic Development to Advance Patient Treatment Act
S. 264, Excellence in Mental Health Act: Sets forth criteria for the certification of federally-qualified community behavioral health centers
S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B Drug Pricing Program (112th Congress)
S. 3187, Food and Drug Administration Safety and Innovation Act: Provisions related to user fee reauthorization and FDA reform (112th Congress)
S. 957, Drug Supply Chain Security Act: Provisions related to supply chain security
S. 959, Pharmaceutical Compounding Quality and Accountability Act: Provisions related to pharmaceutical compounding
S. 1723, No ObamaCare Kickbacks Act of 2013: Provisions related to application of the anti-kickback statute to qualified health plans
S. 2295, Patient Safety and Generic Labeling Improvement Act: Provisions relating to drug safety labeling (112th Congress)
Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including PPACA; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking
Comparative effectiveness policy issues
Academic detailing policy issues
Drug abuse policy issues
General HHS and FDA related advocacy
Biopharmaceutical innovation policy issues
Prescription drug abuse policy issues
FDA accelerated approval policy issues
Unapproved use policy issues
340B Drug Pricing Program policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
Jennifer |
Bryant |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Leo |
Farber |
|
|
|
Lea |
Fisher |
|
|
|
Peter |
Fotos |
|
|
|
Sascha |
Haverfield-Gross |
|
|
|
Valerie |
Jewett |
|
|
|
Colleen |
Maloney |
|
|
|
Cara |
Moon |
|
|
|
Anne |
Pritchett |
|
|
|
Lori |
Reilly |
|
|
|
Jennifer |
Romans |
|
|
|
Nick |
Shipley |
|
|
|
James M. (Mit) |
Spears |
|
|
|
Matt |
Sulkala |
|
|
|
Jeffrey |
Francer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 351, Protecting Seniors' Access to Medicare Act of 2013: Provisions related to the Independent Payment Advisory Board
H.R. 460, Patients' Access to Treatments Act of 2013: Provisions related to capping specialty tier drugs and no cost-sharing above the non-preferred brand tier
H.R. 928, Medicare Prescription Drug Savings and Choice Act of 2013: Provisions related to Part D issues
H.R. 1588, Medicare Drug Savings Act of 2013: Provisions related to Part D issues
H.R. 2810, Medicare Patient Access and Quality Improvement Act: Provisions related to Sustainable Growth Rate (SGR) reform
H.R. 2827, To amend title XVIII of the Social Security Act to allow for fair application of the exceptions process for drugs in tiers in formularies in prescription drug plans under Medicare part D: Provisions related to Medicare Part D Drug Tier Formularies
H.R. 2925, Strengthening Medicare Anti-Fraud Measures Act of 2013: Provisions related to fraud and abuse
H.R. 3392, Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013: Provisions related to lock-in programs
H.R. 3796, Comprehensive Care Payment Innovation Act: Provisions related to alternative payment models
S. 117, Medicare Prescription Drug Price Negotiation Act of 2013: Provisions related to Part D issues
S. 351, Protecting Seniors Access to Medicare Act of 2013: Provisions related to Independent Payment Advisory Board
S. 408, Medicare Prescription Drug Savings and Choice Act of 2013: Provision related to Part D issues
S. 740, Medicare Drug Savings Act of 2013: Provisions related to Part D issues
Deficit reduction policy issues
S. 882, Stop Trafficking of Pills (STOP) Act: Provisions related to lock-in programs (112th Congress)
S. 1365, Part D Beneficiary Appeals Fairness Act: Provisions related to the specialty tier in Part D
S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013: Provisions related to reforming Medicare physician payments
Medicare Prescription Drug Diversion and Abuse Prevention Act: Provisions related to diversion and abuse (no bill number)
Proposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy
Medicaid Program, Covered Outpatient Drugs rulemaking
Medicare sustainable growth rate policy issues
Implementation issues relating to the Physician Payment Sunshine Act, including Medicare, Medicaid, Childrens Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
Jennifer |
Bryant |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Lea |
Fisher |
|
|
|
Valerie |
Jewett |
|
|
|
Colleen |
Maloney |
|
|
|
Cara |
Moon |
|
|
|
Anne |
Pritchett |
|
|
|
Lori |
Reilly |
|
|
|
Jennifer |
Romans |
|
|
|
Nick |
Shipley |
|
|
|
James M. (Mit) |
Spears |
|
|
|
Matt |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 3167, Playing Fair on Trade and Innovation Act: Provisions related to intellectual property
Korea Free Trade Agreement: Implementation issues related to intellectual property, market access and public health
Trans-Pacific Partnership (TPP): Provisions related to intellectual property, market access and public health issues
Mexico and Canada IP and market access issues
Turkey Market Access Issues
India innovation, IP and market access issues
Transatlantic Trade and Investment Partnership (TTIP): Market access, intellectual property, regulatory and other issues
The Agriculture Reform, Food and Jobs Act of 2013/H.R. 1947, Federal Agriculture Reform and Risk Management Act of 2013: Issues related to World Trade Organization (WTO) Brazil Cotton dispute
Issues related to Special 301 and National Trade Estimate (NTE) submissions including intellectual property and market access issues
International market access and intellectual property issues
Biopharmaceutical innovation policy issues
Trade Promotion Authority issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), Patent & Trademark Office (PTO), State - Dept of (DOS), Natl Security Council (NSC), U.S. Trade Representative (USTR), White House Office, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Castellani |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
|
Leo |
Farber |
|
|
|
Lea |
Fisher |
|
|
|
Sascha |
Haverfield-Gross |
|
|
|
David |
Korn |
|
|
|
Colleen |
Maloney |
|
|
|
Jennifer |
Romans |
|
|
|
Nick |
Shipley |
|
|
|
James M. (Mit) |
Spears |
|
|
|
Matt |
Sulkala |
|
|
|
Jeffrey |
Francer |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: http://www.phrma.org/about/member-companies
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |